Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA (2021 - 2025)

ARS Pharmaceuticals' EBITDA history spans 5 years, with the latest figure at -$41.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 182.69% year-over-year to -$41.2 million; the TTM value through Dec 2025 reached -$171.4 million, down 2198.09%, while the annual FY2025 figure was -$171.4 million, 2198.09% down from the prior year.
  • EBITDA for Q4 2025 was -$41.2 million at ARS Pharmaceuticals, up from -$51.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $49.8 million in Q4 2024 and bottomed at -$51.1 million in Q3 2025.
  • The 5-year median for EBITDA is -$15.1 million (2023), against an average of -$13.6 million.
  • The largest annual shift saw EBITDA skyrocketed 815.94% in 2024 before it plummeted 258.95% in 2025.
  • A 5-year view of EBITDA shows it stood at $45.8 million in 2021, then tumbled by 130.61% to -$14.0 million in 2022, then skyrocketed by 50.38% to -$7.0 million in 2023, then surged by 815.94% to $49.8 million in 2024, then crashed by 182.69% to -$41.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EBITDA are -$41.2 million (Q4 2025), -$51.1 million (Q3 2025), and -$45.0 million (Q2 2025).